Mariner, LLC Prothena Corp Public LTD CO Transaction History

Mariner, LLC

$55.8 Billion
Q3 2024

A detailed history of Mariner, LLC transactions in Prothena Corp Public LTD CO stock. As of the latest transaction made, Mariner, LLC holds 323,213 shares of PRTA stock, worth $4.08 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

323,213

Previous 198,035 63.21%

Holding current value

$4.08 Million

Previous $4.09 Million 32.3%

% of portfolio

0.01%

Previous 0.01%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$16.73 - $24.79 $2.09 Million - $3.1 Million	125,178 Added 63.21%	323,213 $5.41 Million
Q2 2024 Aug 13, 2024	BUY	$19.54 - $26.15 $411,688 - $550,954	21,069 Added 11.91%	198,035 $4.09 Million
Q1 2024 May 15, 2024	SELL	$24.75 - $40.66 $36,085 - $59,282	-1,458 Reduced 0.82%	176,966 $4.38 Million
Q4 2023 Feb 14, 2024	BUY	$32.31 - $52.32 $338,996 - $548,941	10,492 Added 6.25%	178,424 $6.48 Million
Q3 2023 Nov 13, 2023	BUY	$47.3 - $70.6 $1.55 Million - $2.32 Million	32,870 Added 24.34%	167,932 $8.1 Million
Q2 2023 Aug 11, 2023	BUY	$48.26 - $78.59 $1.35 Million - $2.2 Million	27,955 Added 26.1%	135,062 $9.22 Million
Q1 2023 May 12, 2023	BUY	$46.97 - $58.27 $3.77 Million - $4.67 Million	80,180 Added 297.77%	107,107 $5.19 Million
Q4 2022 Feb 14, 2023	BUY	$52.05 - $65.0 $515,190 - $643,370	9,898 Added 58.12%	26,927 $1.62 Million
Q3 2022 Nov 10, 2022	BUY	$25.16 - $60.63 $48,785 - $117,561	1,939 Added 12.85%	17,029 $1.03 Million
Q2 2022 Aug 15, 2022	SELL	$22.73 - $39.98 $1.34 Million - $2.36 Million	-59,040 Reduced 79.64%	15,090 $410,000
Q1 2022 May 13, 2022	BUY	$30.27 - $49.22 $1.82 Million - $2.96 Million	60,144 Added 430.03%	74,130 $2.71 Million
Q4 2021 Feb 14, 2022	BUY	$42.11 - $73.26 $588,950 - $1.02 Million	13,986 New	13,986 $691,000

Others Institutions Holding PRTA

# of Institutions

184

Shares Held

42.7M

Call Options Held

162K

Put Options Held

102K

View Full List

About PROTHENA CORP PUBLIC LTD CO

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $592M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

More about PRTA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mariner, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Mariner, LLC with notifications on news.

Account